Assessing IgM antibody levels to aid in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infections
This test includes testing for Chlamydia pneumoniae IgM, and Chlamydia psittaci IgM
Micro-Immunofluorescent Antibody (MIF) Assay
Bedsonia
Chlamydia Antibodies, IgM
Chlamydia pneumoniae (TWAR)
Chlamydia pneumoniae, IgM
Chlamydia psittaci, IgM
Chlamydia TWAR
Chlamydophila
Chlamydophila pneumonia
Chlamydophila pneumoniae
Chlamydophila psattaci
Chlamydophila psittaci
LGV (Lymphogranuloma Venereum)
Lymphogranuloma Venereum (LGV) Antibodies
Ornithosis
Psittacosis
Psittacosis Antibodies
TWAR
TWAR (Chlamydia pneumoniae)
CHLM
This test includes testing for Chlamydia pneumoniae IgM, and Chlamydia psittaci IgM
Serum
For suspected Chlamydia trachomatis infection, order either CTRNA / Chlamydia trachomatis, Nucleic Acid Amplification, Varies or CGRNA / Chlamydia trachomatis and Neisseria gonorrhoeae, Nucleic Acid Amplification, Varies.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.3 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
0.15 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat-inactivated specimen | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 30 days | |
Frozen | 30 days |
Assessing IgM antibody levels to aid in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infections
This test includes testing for Chlamydia pneumoniae IgM, and Chlamydia psittaci IgM
Members of the family Chlamydiaceae are small, nonmotile, gram-negative, obligate intracellular organisms that grow in the cytoplasm of host cells. While there are at least 9 species within the Chlamydia genus, 3 are clinically significant, including Chlamydia trachomatis, Chlamydia pneumoniae, and Chlamydia psittaci.
The chlamydial life cycle can be divided into 2 distinct phases: an extracellular, nonreplicating, infectious stage and an obligate intracellular, replicating, noninfectious stage. The infectious form, or elementary body (EB), attaches to the target cell membrane and enters the cell via a phagosome. After cell entry, the EB reorganizes into reticulate particles (forming inclusion bodies) and binary fission begins. After 18 to 24 hours, reticulate particles condense to form EBs. These new EBs are released, beginning another infection cycle.
C psittaci is the causative agent of psittacosis, a disease characterized by pneumonia, headache, altered mentation, and hepatosplenomegaly. Psittacosis is acquired by airborne transmission from infected birds.
C pneumoniae (formerly known as Taiwan acute respiratory agent and, more recently, as Chlamydophila pneumoniae) causes pneumonia in humans. It is unique because it is a primary pathogen of humans, is spread from human to human, and apparently has no animal or bird host. C pneumoniae is responsible for approximately 10% of pneumonia cases.
Chlamydia pneumoniae
<1:10
Chlamydia psittaci
<1:10
Chlamydia pneumoniae, and Chlamydia psittaci
> or =1:10
IgM endpoint titers of 1:10 or more are considered presumptive evidence of infection.
<1:10
IgM endpoint titers below 1:10 suggest that the patient does not have a current infection. These antibody levels may be found in patients with either no history of chlamydial infection or those with past infection whose antibody levels have dropped below detectable levels.
Specimens collected too early during primary infection may not contain detectable antibodies. If chlamydial infection is suspected, a second specimen should be collected 10 to 21 days later and tested in parallel with the original specimen.
During a primary Chlamydia infection, the early antibody response may be cross-reactive with multiple Chlamydia species.
This assay does not report antibodies detected against Chlamydia trachomatis. Sera from suspected cases of lymphogranuloma venereum (LGV) should be tested by a Lymphogranuloma Venereum Differentiation Antibody Panel. LGV testing is not performed by Mayo Clinic Laboratories; call 800-533-1710 for assistance with ordering.
Due to the limited sensitivity and specificity of Chlamydia serologic tests, patients with suspected C trachomatis infection should be tested by a molecular method (eg, CTRNA / Chlamydia trachomatis, Nucleic Acid Amplification, Varies or CGRNA / Chlamydia trachomatis and Neisseria gonorrhoeae, Nucleic Acid Amplification, Varies) to evaluate for current/active infection.
1. Schlossberg D. Psittacosis (due to Chlamydia psittaci). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2320-2322
2. Hammerschlag MR, Kohlhoff SA, Gaydos CA. Chlamydia pneumoniae. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2323-2331
The microimmunofluorescent antibody assay is a 2-stage "sandwich" procedure. In the first stage, the patient serum is diluted in phosphate-buffered saline, added to appropriate slide wells in contact with the substrate, and incubated. After incubation, the slide is washed in buffered saline to remove unbound serum antibodies. In the second stage, each antigen well is overlaid with fluorescein-labeled antibody to IgM. The slide is incubated, allowing antigen-antibody complexes to react with the fluorescein-labeled anti-IgG. After the slide is washed, dried, and mounted, it is examined using fluorescence microscopy. Positive reactions appear as bright apple-green fluorescent elementary bodies with a background matrix of yolk sac. Semiquantitative endpoint titers are obtained by testing serial dilutions of positive specimens.(Schachter J. Chlamydiae [Psittacosis-Lymphogranuloma Venereum-Trachome Group]. In: Lennette E, Balows A, Hausler W, Shadomy H, eds. Manual of Clinical Microbiology. 4th ed. ASM Press; 1985: 856-861; Smith T. Chlamydia. In: Schmidt N, Emmons R, eds. Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. APHA; 1989: 1165-1198)
Monday, Thursday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
86632 x 2
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CHLM | Chlamydia IgM, IFA, S | 10849-8 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
619390 | C. pneumoniae IgM | In Process |
619391 | C. psittaci IgM | In Process |
Change Type | Effective Date |
---|---|
New Test | 2023-03-28 |